相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway
Rong Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition
Yan Q. Chen et al.
JOURNAL OF LIPID RESEARCH (2021)
Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly
Jorge Simon et al.
CELL METABOLISM (2020)
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics
Simona Cernea et al.
DRUGS (2020)
High density lipoprotein promotes nascent apolipoprotein A-V secretion from mRNA transfected cells
Irina Romenskaia et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway
Rong Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism
Trudy M. Forte et al.
CURRENT DRUG TARGETS (2015)
Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers
Qin Feng et al.
PATHOLOGY (2015)
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
Davy Vancampfort et al.
WORLD PSYCHIATRY (2015)
Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant
Kirstin Albers et al.
ATHEROSCLEROSIS (2014)
Triglycerides and cardiovascular disease
Borge G. Nordestgaard et al.
LANCET (2014)
The role of apolipoprotein A5 in obesity and the metabolic syndrome
Xiao-Yan Zheng et al.
BIOLOGICAL REVIEWS (2013)
Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro
Alberto Canfran-Duque et al.
JOURNAL OF LIPID RESEARCH (2013)
Olanzapine Activates Hepatic Mammalian Target of Rapamycin: New Mechanistic Insight into Metabolic Dysregulation with Atypical Antipsychotic Drugs
Robin H. Schmidt et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Influence of apolipoprotein A-V on hepatocyte lipid droplet formation
Xuan Gao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Apolipoprotein A-V dependent modulation of plasma triacylglycerol: A puzzlement
Vineeta Sharma et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2012)
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Ariel Brautbar et al.
ATHEROSCLEROSIS (2011)
Apolipoprotein A-V; a potent triglyceride reducer
Stefan K. Nilsson et al.
ATHEROSCLEROSIS (2011)
Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults A Systematic Review and Meta-analysis
Alicia Ruelaz Maher et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion
Anna M. Blade et al.
JOURNAL OF LIPID RESEARCH (2011)
Increasing off-label use of antipsychotic medications in the United States, 1995-2008
G. C. Alexander et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice
Sehyoun Yoon et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole
H. G. Shertzer et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naive Schizophrenia Patients
Jimmi Nielsen et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-α
Xian-sheng Huang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
Christoph U. Correll et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice
Roberto Coccurello et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
Effect of apolipoprotein AN on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice
Lisa Nelbach et al.
JOURNAL OF LIPID RESEARCH (2008)
Rare APOA5 mutations -: Clinical consequences, metabolic and functional effects -: An ENID review
Philippa J. Talmud
ATHEROSCLEROSIS (2007)
Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells
Li-Hung Yang et al.
PHARMACOLOGICAL RESEARCH (2007)
A lipid-based model for the creation of an escape hatch from the endoplasmic reticulum
Hidde L. Ploegh
NATURE (2007)
Prediction of genetic risk for metabolic syndrome
Yoshiji Yamada et al.
ATHEROSCLEROSIS (2007)
Association of human serum apolipoprotein A5 with lipid profiles affected by gender
Shui-Ping Zhao et al.
CLINICA CHIMICA ACTA (2007)
Lipid droplets: a unified view of a dynamic organelle
S Martin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants
I Grosskopf et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase
M Merkel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia
CP Oliva et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis
FG Schaap et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Analysis of apolipoprotein A5, C3, and plasma triglyceride concentrations in genetically engineered mice
N Baroukh et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Structure and interfacial properties of human apolipoprotein A-V
RB Weinberg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice
LA Pennacchio et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Apolipoprotein A-V - A novel apolipoprotein associated with an early phase of liver regeneration
HN van der Vliet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing
LA Pennacchio et al.
SCIENCE (2001)
分享论文
